Articles published by Incyte
![](https://mms.businesswire.com/media/20221202005043/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
December 02, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20221117005001/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Present at Upcoming Investor Conferences
November 17, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20221107005169/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 07, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20221103005878/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
More than 50 Abstracts from Incyte’s Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting
November 03, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20221101005407/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
November 01, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20221019006152/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20221011005007/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Report Third Quarter Financial Results
October 11, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20221004005151/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte Names New Member to Its Board of Directors
October 04, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20221003005269/en/1589087/4/Villaris_logo.jpg)
![](https://mms.businesswire.com/media/20220826005244/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20220824005066/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20220823005001/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Present at Upcoming Investor Conference
August 23, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20220802005416/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
August 02, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20220718005819/en/1513198/4/OpzeluraProductImage.jpg)
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo
July 18, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20220712005062/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Report Second Quarter Financial Results
July 12, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20220526005194/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
May 26, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20220524005029/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Present at Upcoming Investor Conference
May 24, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20220504006208/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20220504005006/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Present at Upcoming Investor Conference
May 04, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20220503005331/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
May 03, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20220428005807/en/1436628/3/MaruhoLogo.jpg)
Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
April 28, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20220421006067/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20220412005102/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Report First Quarter Financial Results
April 12, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20220326005005/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20220325005243/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20220318005248/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20220215005154/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Present at Upcoming Investor Conference
February 15, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20220203005010/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Present at Upcoming Investor Conference
February 03, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20220125006021/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte Provides Update on Parsaclisib and MCLA-145
January 25, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20220118005069/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
January 18, 2022
From Incyte
Via Business Wire
Tickers
INCY
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.